McNA343

Confirm delete?

McNA343

Zoom

Cat No: 30961

Biochemicals - Receptor Pharmacology

McNA343 is a partial agonist of muscarinic acetylcholine receptors (Kis = 5, 1, 5, 0.2, and 7.6 µM for M1-5 receptors, respectively, in radioligand binding assays).{56099} It induces contraction of isolated human umbilical veins (EC50 = 1.23 µM), an e...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-[[[(3-chlorophenyl)amino]carbonyl]oxy]-N,N,N-trimethyl-2-butyn-1-aminium, monochloride

Correlated keywords:

7614-29-1 Mc NA 343 McN A 343 11 A343 M 1 3 4 5 CHOK1 K 1 McN 34311

Product Overview:
McNA343 is a partial agonist of muscarinic acetylcholine receptors (Kis = 5, 1, 5, 0.2, and 7.6 µM for M1-5 receptors, respectively, in radioligand binding assays).{56099} It induces contraction of isolated human umbilical veins (EC50 = 1.23 µM), an effect that can be reversed by various M1 muscarinic receptor selective antagonists. McNA343 also inhibits forskolin-induced cAMP production in CHO cells expressing M1 or M4 receptors, as well as phosphatidylinositol hydrolysis in CHO-K1 cells expressing M3 receptors and CHO cells expressing M5 receptors. Intrathecal administration of McNA343 inhibits compulsive hindlimb neck-scratching behavior induced by 5’-guanidinonaltrindole (GNTI) in mice. It has nootropic activity, enhancing spontaneous working memory in the Y maze in wild-type mice, and it reverses learning and memory impairments induced by bulbectomy in mice in a passive avoidance test.

Size	10 mg
Shipping	dry ice
CAS Number	55-45-8
Molecular Formula	C₁₄H₁₈ClN₂O₂ • Cl
SMILES	ClC1=CC=CC(NC(OCC#CC[N+](C)(C)C)=O)=C1.[Cl-]
Molecular Weight	317,2
Formulation	A solid
Purity	≥98%
Custom Code	2924.29
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.